Analysis of P-glycoprotein expression and function in the homozygous vs the heterozygous allelic variants of the MDR1 gene at time of relapse/refractory disease
| . | GG or TT . | GT . | P value . |
|---|---|---|---|
| MDR1 | |||
| MRK16 | |||
| Median | 1.54 | 2.14 | .15 |
| Range | 1.02-5.45 | 1.18-5.55 | |
| N | 13 | 17 | |
| MRK16/CD34 | |||
| Median | 1.88 | 2.68 | .22 |
| Range | 1.49-4.90 | 1.46-9.6 | |
| N | 7 | 7 | |
| UIC2 | |||
| Median | 1.56 | 2.28 | .22 |
| Range | 1.12-6.39 | 0.99-5.24 | |
| N | 13 | 17 | |
| UIC2/CD34 | |||
| Median | 1.67 | 2.72 | .10 |
| Range | 0.86-7.34 | 1.69-5.15 | |
| N | 7 | 8 | |
| PSC/Rho | |||
| Median | 1.08 | 1.14 | .30 |
| Range | 0.81-1.85 | 0.84-2.19 | |
| N | 13 | 17 | |
| PSC/Rho/CD34 | |||
| Median | 1.21 | 1.42 | .40 |
| Range | 1.07-1.72 | 0.82-3.26 | |
| N | 9 | 9 |
| . | GG or TT . | GT . | P value . |
|---|---|---|---|
| MDR1 | |||
| MRK16 | |||
| Median | 1.54 | 2.14 | .15 |
| Range | 1.02-5.45 | 1.18-5.55 | |
| N | 13 | 17 | |
| MRK16/CD34 | |||
| Median | 1.88 | 2.68 | .22 |
| Range | 1.49-4.90 | 1.46-9.6 | |
| N | 7 | 7 | |
| UIC2 | |||
| Median | 1.56 | 2.28 | .22 |
| Range | 1.12-6.39 | 0.99-5.24 | |
| N | 13 | 17 | |
| UIC2/CD34 | |||
| Median | 1.67 | 2.72 | .10 |
| Range | 0.86-7.34 | 1.69-5.15 | |
| N | 7 | 8 | |
| PSC/Rho | |||
| Median | 1.08 | 1.14 | .30 |
| Range | 0.81-1.85 | 0.84-2.19 | |
| N | 13 | 17 | |
| PSC/Rho/CD34 | |||
| Median | 1.21 | 1.42 | .40 |
| Range | 1.07-1.72 | 0.82-3.26 | |
| N | 9 | 9 |
For P-gp expression, the monoclonal antibodies MRK16 and UIC2 were used; for P-gp function, the PSC/Rho 123 retention ratio was used. In samples with more than 10% CD34 expression, the variables were also evaluated in the CD34+ subfraction of the blasts. TheP values indicate the differences between the homozygous and heterozygous patients.